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ABSTRACT
Objectives: To assess sex hormones in men with obesity and prostate cancer (PCa) and to study
association between androgens and the pathogenesis biology of PCa in vitro.
Subjects and methods: One hundred and eighty-one men older than 45 years selected from of
a population attending to Urology departments screening for PCa, (78 participants without PCa
and 103 patients with PCa). All participants were assessed for body mass index (BMI), age,
Gleason score, and PSA. Endocrine profile was determined for LH, total testosterone (TT), 17b-
estradiol (E2), prolactin and leptin. Biochemical profile (HbA1c, triacylglycerols and lipoproteins)
was also determined. In vitro experiments were also performed, involving the study of 5a-
dihydrotestosterone (DHT) and E2 in the presence of adipocyte-conditioned medium (aCM).
Results: All variables were continuous and described a Gaussian distribution unless mentioned.
To determine the relation of aggressiveness, variable were transformed into categories. Thus,
PCa aggressiveness is associated with the increase of age and BMI (p< .0001) but with is
decreased with TT and E2 (p< .05). Moreover, adipocyte-secreted molecules increase aggressive-
ness of PCa cells in vitro. Lastly, DTH but not E2 enables invasiveness in vitro.
Conclusions: It was observed a coexistence of hormone axis profile alteration with sex hor-





Across the world, prostate cancer (PCa) is the second
most frequent type of Cancer among men [1]. In par-
ticular, in the North Portugal it is the more common,
and about 22.2% of men who have cancer, have PCa.
Moreover, in 2009 it was accounted that 1733 men
had PCa and in 2015 the number increased to 2351,
representing an increase of 35.7% and an increase of
74.0% is expected from 2009 to 2020 [2].
Evidence has supported obesity as a risk factor for
both benign prostate hyperplasia (BPH) and PCa. The
World Health Organization and The National Institutes
of Health define overweight as a body mass index
(BMI) of greater than 25 kg/m2, and obesity as BMI of
greater than 30 kg/m2 [3].
It is long recognized, that testosterone is a crucial
lipid hormone that plays a major role in key metabolic
and pathophysiological processes such as obesity and
cancer [4–7]. The increased central adiposity (fat mass)
and reduced lean mass is related with hypogonadism
(low levels of testosterone) [8,9]. These anatomic fea-
tures are closely related to metabolic dysfunction.
Particularly, metabolic features associated to testoster-
one deficiency include energy metabolism imbalance
such as impaired glucose regulation, reduced insulin
sensitivity and dyslipidemia [10,11].
Testosterone may be found in different forms. There
is “free” testosterone, that is not bound to any proteins
or blood transporters and it is recognized to be the
most abundant in the body. However, testosterone may
also be bound to albumin and to sex hormone-binding
globulin (SHBG). In this form testosterone is not active.
Testosterone is often converted to dihydrotestosterone
(DHT) by a set of widely distributed enzymes, 5a-reduc-
tases (EC. 1.3.1.22). DHT is five times more potent than
testosterone and is the preferred form used by the cells
of prostate, skin, and hair follicles [12].
Androgen levels change with age. It is estimated
that testosterone levels decline about 1% per year
after the age of 30. When testosterone decreasing
levels in the aging male cause discomfort and loss of
quality-of-life such as erectile dysfunction (ED), muscle
strength, bone strength [13], and fatigue, hormone
therapy must be considered [14,15].
Testosterone low-levels or even deficiency is not
only linked with age. In fact, testosterone deficiency is
also associated with insulin resistance and the meta-
bolic syndrome (MetS), reduced bone density and
increased visceral obesity. Thus, several authors dis-
cussed whether restoring testosterone normal physio-
logical levels may exert benefits to elderly men, not
only in the metabolic fitness (reduces obesity,
increases insulin sensitivity) but also libido improve-
ment and health-related quality of life [16–18].
Regarding the role of testosterone on prostate can-
cer (PCa) there is still some discussion among the sci-
entific community, since there are several discrepant
studies. While numerous longitudinal studies have rec-
ognized an association between high levels of TT and
subsequent development of PCa [19,20] other smaller,
well-designed studies have demonstrated the oppos-
ite, that is, increased PCa risk in patients with lower
testosterone levels [21,22].
Nevertheless, considered by most scientific and clin-
ical community one of most important and perhaps
one of the most robust study on the role of testoster-
one and PCa relationship comes from the study of the
a 5a-reductase inhibitor, dutasteride, the REDUCE trial
(Reduction by Dutasteride of Prostate Cancer Events)
[23]. The study included two arms, the placebo arm
and the Dutasteride arm, and enrolled initially 8231
patients distributed 4126 by placebo and 4105 by
dutasteride arms. In analyzing the placebo arm, Muller
et al. identified no association of testosterone or DHT
with PCa incidence nor Gleason grade [24].
Thus, a large number of scientific evidence have
somehow linked serum testosterone levels and/or its
carrier (SHBG) to cancer and metabolic disturbances
such as metabolic syndrome and diabetes [15,25–30]. In
fact, androgen deprivation has been associated to worst
glycemic control and increase cardiovascular biochem-
ical risk factors in diabetic prostate cancer patients [31].
However, the exact type of the observed relations
remains indeterminate. These ambiguities may be
endorsed to the high variability of the associations
reported. The most relevant evidence suggests that asso-
ciations may differ according to age and BMI [32–34].
Aims
Considering these facts, the current study aims to
evaluate the association between hormonal and
biochemical profile with the occurrence and aggres-
siveness (Gleason Score) of PCa in the Portuguese
obese men from the North of Portugal. In order to
achieve that purpose, we have analyzed a set of
patients from this region with and without PCa. Also,
we have studied the effect of sexual hormones (testos-
terone and estradiol) on PCa cells in vitro within an
environment enriched by the secreted signaling mole-
cules of adipose cells.
Material and methods
Sample size and characteristics
The current study presents a cross-sectional design
and included 181 men older than 45 years, who were
referred to routine urological evaluation. The study
protocol was approved by our local ethical committee,
and all patients signed the written informed consent.
The indication for prostate biopsy is based on the
prostate specific antigen (PSA) blood test, its evolution
over time and on prostate changes regarding the con-
sistency or shape detected by direct examination
(prostate touch) or both.
Socio-demographic information was obtained, and
blood samples were collected for biochemical and
hormonal analysis.
Blood collection
Patients who submitted for ultrasound-guided pros-
tate biopsy were given a venous blood sample prior
to any prostatic manipulation (rectal examination) and
transrectal echography in Vacutainer BD tubes, a tube
without any additive, which were subsequently centri-
fuged at 3500 r.p.m. and the separate serum for the
determination of the aforementioned hormones and
biochemical markers.
Recommendations for the handling and storage of
samples are provided by the National Committee for
Clinical Laboratory Standards.
Laboratory tests
For the determination of all the hormones included in
the study, commercial reagent kits from Roche (Roche
Diagnostics) developed for use in the E170 modular
automatic analyzer were used.
The method used for the determination of all hor-
mones was the electrochemiluminescent assay (ECLIA)
by means of competitive or sandwich approach.
The reagents used were those indicated by the
manufacturer and where necessary calibrations were
carried out and the calibrators used were those rec-
ommended by the respective manufacturers.
For each series of determinations, control sera were
inserted. These sere were acquired in the market, in
three levels of concentration (low, normal and high).
The determinations were only made after validating
the results of the quality control, which were always
within the values defined by the Quality
Control platform.
Hormonal and biochemical profile
The hormonal profile in the current study was per-
formed in the patients who underwent the ultra-
sound-guided prostate biopsy and were defined at the
beginning of the study, being constituted by the fol-
lowing hormones: Leptin, Prolactin, Estradiol,
Luteinizing Hormone, and Total Testosterone. The nor-
mal range considered in the present study were of
0.7–5.3 ng/mL for Leptin, 4.04–15.2 ng/mL for Prolactin,
7.63–42.6 pg/mL for Estradiol (E2), 1.7–8.6 mUI/mL for
Luteinizing Hormone, and 2.8–8.0 ng/mL for Total
Testosterone. Values below or higher than the normal
range, are considered as low or high respectively.
Moreover, the biochemical profile includes glycated
hemoglobin HbA1c, triacylglycerols (TAGs), total chol-
esterol (CHOT) and its fractions, such as high-density
lipoproteins (HDL-c), low-density lipoproteins (LDL-c)
and very low-density lipoproteins (VLDL). Normal
ranges of such biochemical parameters in use in the
present study are 4.0–6.0% for HbA1c, 40–160mg/dL
for TAGs, 0–200mg/dL for CHOT, 35–55mg/dL for
HDL-c mg/dL, 0–130mg/dL for LDL-c and 3–56mg/dL
for VLDL. As before, we have considered the values
inferior or superior to the normal range as low or high
respectively.
Cell culture and in vitro treatments
For the current work 3T3-L1 (purchased from
American Type Culture Collection) cells were cultured
in DMEM (Dulbeccos Modified Eagles Medium with
4.5 g/L Glucose and L-Glutamine, without Sodium
Pyruvate. Santa Cruz Biotechnology, Inc.), supple-
mented with 10% FBS, and 1000 units/mL gentamycin
solution, maintained in T-25 tissue culture flasks in 5%
CO2/95% air at 37 C in a humidified incubator.
Human prostate cancer cell line, PC3 were cultured
in RPMI-1640 medium (Gibco, Life technologies,
52400–025, USA) supplemented with 10% of Fetal
Bovine Serum (Gibco, Life technologies, 10270, USA)
and 1% antibiotic/antimycotic (Gibco, Life
technologies, 10270, USA). The cells were maintained
in a humidified chamber with 95% air and 5% CO2 at
37 C. The cells were used between passages 2 and 8.
Adipocyte differentiation and conditioned medium
(CM) collection
3T3-L1 pre-adipocytes were propagated and allowed
to reach confluence. After 2 days (day 0), the differen-
tiation was initiated by addition of a hormonal mixture
composed of 2 lM insulin, 1 lM dexamethasone and
0.25mM isobutylmethylxanthine. Three days after (day
3), the induction medium was replaced by complete
medium supplemented with insulin only. At day 6 cul-
tures were washed twice in phosphate buffered saline
and incubated in serum-free medium. After 24 h (day
7), medium was harvested from the adipocytes cul-
tures, spun for 3000 g for 5min and the supernatant
(mature adipocytes conditioned medium) was stored
at 80 C for the subsequent treatments. This condi-
tioned medium (CM) is rich in adipokines which are
globally referred as secretome.
Cell culture treatments
Afterwards, prostate cells were divided in two distinct
groups. On one hand, prostate cancer cells PC3 were
grown under the influence of the mature adipocytes
secretome. On other hand, the control group con-
sisted in the PC3 cells cultured in the absence of 3T3-
L1 conditioned medium with low levels of glu-
cose (LG).
Treatments were performed using Dulbecco’s
Modified Eagle Medium (DMEM), without supplemen-
tation. To assay the hormone effects on cell growth,
cells were grown for 24 h in DMEM medium (Sigma-
Aldrich) supplemented with different concentrations of
hormones, testosterone (Fluka), and 17b-estradiol (E2)
(Sigma-Aldrich) dissolve in 0,1% of DMSO. The most
significant concentration was used to perform an
Injury assay.
Cell viability assay
After 24 h incubation of 1 105 cells/mL with the dif-
ferent treatments, culture medium was replaced by
PBS and 20mL of the MTT reagent (Abcam, USA), was
added into each 96-plate well followed by 3 h incuba-
tion period. Color development was determined by
measuring absorbance at 550/650 nm.
Injury assay and computational
stereology analysis
Confluent PC3 monolayers on 24-plate well, were
wounded with a 10-ll pipette tip. Twenty-four hours
after treatment, the migrated distance was photo-
graphed under an inverted microscope (Nikon
Instruments Inc., Melville, NY) at a 200x magnification
and the scratch closure was determined by measuring
the injury width by means of bioinformatics analysis
using Image J software (U. S. National Institutes of
Health, Bethesda, Maryland) with a macro specially
designed for injury assays designated as Wound
Healing Tool [35].
Statistical analysis
Sample size was calculated a priori using GPower ver-
sion 3.1.9.3 [36,37], designed to detect statically signifi-
cant Pearson Correlation Coefficients of 0.5 for level of
significance a error of 5% and a power of 90% (1-b)
the sample should be at least 86 control individuals
and 86 prostate cancer (PCa) patients. The sample was
stratified into two groups, according to presence/
absence of prostate carcinoma. Student t-test was
used to compare means of two different samples. Chi-
square test was used to compare categorical data.
Kolmogorov–Smirnov and Levene’s test were used to
determine normality of populations and variances. All
the studied variables are normally distributed. Data
are presented as mean± standard deviation of the
mean (SEM), unless otherwise stated.
All statistical analyses were performed with IBM
SPSS 20 (SPSS Inc., Chicago, IL). All statistical tests
were two-sided and p< .05 was considered statistically
significant and plotted using GraphPad Prism 6.0
(GraphPad Software Inc.).
Results
Clinical and anthropometric characterization
The current study presents a cross-sectional study and
included 181 men attending the Urology Department
of CHUP (Central Hospital from the University of
Porto), 78 participants without PCa and 103 patients
with PCa. The age ranges from 46 to 85 years old. The
overall mean of ages amongst participants was of
66.4 ± 8.5 (mean± standard deviation) stratified by
68.1 ± 8.4 versus 64.1 ± 8.1 regarding the participants
with and without cancer, respectively (Table 1).
All men consent to be submitted to anthropometric
characterization (weight and height) in order to deter-
mine the Body Mass Index (BMI) according to WHO
recommendations [3]. Thus, the overall BMI was of
26.75 ± 3.88 kg/m2 classifying this sample, generally as
overweight. When looking to BMI by groups, it was
stablished as 28.51 ± 3.88 kg/m2 versus 24.41 ± 2.34 kg/
m2 in the arm with and without cancer respectively
(Table 1).
The indication for prostate biopsy was mainly based
on the PSA blood test and/or on prostate changes by
direct examination. Thus, the global mean of tPSA
(total PSA) was of 17.18 ± 29.58 ng/mL, being different
amongst participants with and without cancer, varying
from 24.65 ± 37.30 ng/mL and 7.19 ± 4.13 ng/mL
respectively (Table 1).
Hormonal and metabolic characterization of
participants
Several hormones were characterized. The hypothal-
amus pituitary testicular axis was measured using
luteinizing hormone (LH) and total testosterone (TT).
Estradiol (E2), an aromatized form of a testosterone
was also analyzed. Considering means (±SD) of both
arms with or without PCa no significant changes of
such hormones were observed. Global levels of LH are
of 7.11 ± 6.09 mUI/mL being of 7.94 ± 7.21 mUI/mL
and 5.99 ± 3.92 mUI/mL in men with and without PCa
respectively. Also, regarding TT, the global levels of
this androgen were of 3.67 ± 1.90 ng/mL and the levels
in people with and without PCa were of
3.27 ± 1.84 ng/mL and 4.21 ± 1.85 ng/mL respectively.
Estradiol (E2) an end product of Aromatase using









Mean SD Mean SD Mean SD
Age (y.o.) 66.38 8.53 68.12 8.45 64.06 8.12
BMI (kg/m2) 26.75 3.88 28.51 3.88 24.41 2.34
tPSA (ng/mL) 17.18 29.58 24.65 37.30 7.19 4.13
LH (mUI/mL) 7.11 6.09 7.94 7.21 5.99 3.92
TT (pg/mL) 3.67 1.90 3.27 1.84 4.21 1.85
E2 (pg/mL) 22.89 10.56 22.93 11.17 22.84 9.75
PROL (ng/mL) 10.33 8.90 8.55 3.83 11.63 11.10
LEPT (ng/mL) 13.84 21.93 15.26 23.60 11.93 19.45
HbA1c (%) 5.72 0.65 5.74 0.70 5.70 0.58
TAG (mg/dL) 157.46 79.54 168.40 90.87 142.82 58.65
CHOT (mg/dL) 192.27 37.82 192.96 38.62 191.35 36.95
HDL (mg/dL) 52.53 14.53 54.02 14.92 50.53 13.83
LDL (mg/dL) 104.15 33.07 101.40 31.52 107.83 34.91
VLDL (mg/dL) 31.24 15.40 32.43 17.66 29.66 11.64
BMI: Body Mass Index; tPSA– total Prostate Specific Antigen; LH:
Luteinizing hormone; TT: Total Testosterone; E2: Estradiol; Prol: Prolactin;
Lept: Leptin; Hb A1c: Glycated hemoglobin A, fraction 1c; TAG:
Triacylglycerols; CHOT: Cholesterol, total fraction; HDL: High-density lipo-
protein; LDL: Low-density lipoprotein; VLDL: Very low-density lipoprotein;
SD: Standard deviation.
testosterone as substrate, was globally of
22.89 ± 10.56 pg/mL but also very similar amongst the
two arms varying from 22.93 ± 11.17 pg/mL to
22.84 ± 9.75 pg/mL in patients with and without PCa,
respectively. Finally, Prolactin a hormone related to
both sexual health and metabolism [38] was also eval-
uated. Men with PCa have lower levels of prolactin.
Thus, these values ranged from 8.55 ± 3.83 ng/mL to
11.63 ± 11.10 ng/mL in patients with and without PCa
(Table 1).
In what concerns to metabolic profile of the partici-
pants, men with PCa have higher levels of Leptin than
men without PCa. In those arms, the mean± SD of
Leptin was of 15.26 ± 23.60 ng/mL in PCa men and of
11.93 ± 19.45 ng/mL in men without PCa. The percent-
age of glycated hemoglobin HbA1c was determined.
The average of this advanced glycation end-product
(AGE) was very similar in both groups: 5.74 ± 0.70%
and 5.70 ± 0.58% for participants with and without
PCa. Regarding TAGs, patients with PCa had higher
levels of these lipids. Thus, comparing patients with
PCa with people without PCa the ranges of such lipids
were 168.40 ± 90.87mg/dL and 142.82 ± 58.65mg/dL,
respectively (Table 1).
Considering lipoprotein profile, as aforementioned
we have measured all the cholesterol fractions. First of
all, total cholesterol (CHOT) presents no differences
between the two groups in study. CHOT values ranges
from 192.96 ± 38.62mg/dL to 191.35 ± 36.95mg/dL in
men with and without PCa respectively. Additionally,
LDL-c fraction was measure and no significant differ-
ences were found however people with no cancer pre-
sented higher mean values. Patients with PCa
presented a mean of values of 101.40 ± 31.52mg/dL of
these lipoprotein and patients with no cancer, pre-
sented an average value of 107.83 ± 34.91mg/dL.
Similarly, regarding HDL-c no differences were found
amongst the arms in study but this time, patients with
PCa presented the higher values. Hence, patients pre-
sented a mean of 54.02 ± 14.92mg/dL of HDL-c, con-
trasting with healthy participants that presented
50.53 ± 13.83mg/dL of this lipoprotein. Likewise, VLDL
fraction was of 32.43 ± 17.66mg/dL in people with PCa
opposing with the mean of 29.66 ± 11.64mg/dL
belonging to healthy subjects (Table 1).
Correlations between clinical and
biochemical profile
Correlation between continuous variables was deter-
mined by Pearson Correlation Coefficient or PCC. PCC
is represented by the symbol q (rho or r). PCC value
has a value between þ1 and 1, where 1 is total posi-
tive linear correlation, 0 is no linear correlation, and
1 is total negative linear correlation. The evaluation
of categorical variables (e.g. Gleason Score) were
determined by means of crosstabulations and estima-
tion by Chi-square test (v2) statistics.
When comparing the categories of negative/posi-
tive cases of PCa distributed by Gleason score and
BMI stratified by normal weight (NW), overweight
(OW) and Obese (OB), the differences were signifi-
cantly strong (p< .0001) estimated by v2-test
(Figure 1).
Similarly, evidence shows that tumor aggressiveness
was correlated with age. Age values were transformed
into an ordinal category of five classes of 10 years old
each: the first class was of 45 to 54 years old (y.o.), the
second of 55 to 64 y.o., and successively until the last
class that included all the participants older than
85 years. (Figure 1).
Furthermore, when participants were stratified by
normal interval ranges of TT, and divided into three
groups named “low”, “normal”, and “high”, strong sig-
nificantly differences (p< .0001) were found when
compared to Gleason Score. Lower levels of TT predict
higher tumor aggressiveness (Figure 1).
The same approach was followed for several con-
tinuous clinical and biochemical variables.
Stratification into three groups designated as “low”,
“normal”, and “high” were implemented according to
normal ranges of such variable. When Chi-square sta-
tistics was executed against each variable in study, it
demonstrated strong significant differences with Age
and BMI, with several hormones, namely Luteinizing
Hormone, Testosterone, Estradiol and Prolactin. Also,
significance was found in lipoprotein markers LDL and
VLDL (Table 2).
Finally, the several continuous clinical and biochem-
ical variables in study were correlated with each other.
All variables were normally distributed and Pearson
correlation coefficient (PCC) was determined to all var-
iables two-by-two. The results are summarized in
Table 3.
Briefly, tPSA (total prostate specific antigen) was
inversely correlated (p< .05) with total Testosterone
(TT) levels. Likewise, BMI was also strongly inversely
correlated with TT levels (p< .0001). Another negative
correlation with BMI was the association between
weight status and the levels of Prolactin (p< .0001).
Nevertheless, BMI was positively correlated with LH
(p< .05), HbA1c (p< .05) and TAGs (p< .05).
With age several hormone and metabolic compo-
nents of the body are known to be deteriorated.
In the present sample of patients with prostate dis-
ease, age itself is also associated with increased of LH
(p< .0001) as well as with decreased TAGs (p< .05),
CHOT (p< .0001) and LDL (p< .0001). All outputs of
the PCC statistics are summarized in Table 3.
Taking into considerations all data mentioned, we
tried to molecularly dissect in vitro the role of some
parameters that increased aggressiveness of PCa such
as BMI and some hormone levels in well stablished
cellular models of prostate cancer, namely using PC3
cell lines. Obviously, BMI can’t be mimiced in vitro.
However, a good cellular alternative is to in vitro grow
adipocytes and mature them to up take and store lip-
ids and then. At this stage, the adipocyte-secreted
molecules such as hormones, cytokines, and adipo-
kines, among others is collected (the all bunch of
adipocyte-secreted molecules are considered as secre-
tome from now on). This is achieved, as mentioned in
materials and methods section, by collecting the adi-
pocyte-conditioned medium (aCM) was add it to can-
cer cells in culture. In the next section of results, we
will reveal the effect of aCM on cell growth and
aggressiveness on PC3 was well as the effect of testos-
terone and E2 in vitro.
Adipocyte secretome characterization
Numerous growth-factors, adipokines, cytokines, and
angiogenesis-related molecules were secreted by
mature adipocytes 3T3-L1 in culture (secretome) into
the medium. That adipocyte-conditioned medium was
collected (aCM), analyzed and used in PCa cells PC3.
Table 2. Chi-square (v2) of Gleason score (tumor aggressiveness) in relation to clinical and biochemical profiles.
Variables (statistics)
Endocrine profile Metabolic profile
Age BMI LH TT E2 PROL LEPT HbA1c TAG CHOT HDL LDL VLDL
GLEASON Score v2 255,3** 69.29** 12.26* 92.41** 97.41** 120.01** 8.39 10.7 5.39 8.00 13.34 11.58* 13.20*
p-value .000 .000 .031 .000 .000 .000 .136 .058 .370 .152 .205 .041 .014
BMI: Body Mass Index; LH: Luteinizing hormone; TT: Total Testosterone; E2: Estradiol; Prol: Prolactin; Lept: Leptin; Hb A1c: Glycated hemoglobin A, frac-
tion 1c; TAG: Triacylglycerols; CHOT: Cholesterol, total fraction; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; VLDL: Very low-density lipo-
protein. p<.05; p<.001.
Figure 1. Ponderal profile of Urology patients. More aggressive forms of prostate cancer are associated (v2) with overweight and
obesity (p< .0001). NW: Normal weight; OW: overweight; OB:obesity. Age was also significantly associated (p< .0001) to tumor
aggressiveness which increases to the age of the patient. Normal levels of testosterone ranging from 2.8–8.0 ng/mL. Inferior and
superior levels were considered as low or high respectively. Tumor aggressiveness was significantly (p< .0001) associated to low
levels of testosterone. Without prostate cancer (white) and with prostate cancer (other colors).
The hormonal profile of aCM was of 0.257 ± 0.09
mUI/mL for LH, 0.061± 0.004 ng/mL for TT,
227.6 ± 30.4 pg/mL for E2 and 0.047 ± 0.000 for
Prolactin. Regarding biochemical profiles, adipocyte
secretome was composed by 155.1 ± 27.4mg/dL of
glucose, 102.0 ± 35.4mg/dL of TAGs and 4.0 ± 1.8mg/
dL of CHOT. Our group has also analyzed extensively
the secretome of adipocytes in previous studies
[39,40] by proteomic approaches including microar-
rays. Briefly, it is observed in the secretome increased
levels of VEGF, TIMP-1, and endocan that control
angiogenesis. Also increased levels of the interleukin
(IL) family of cytokines: IL-6, IL-11, and leukemia inhibi-
tory factor (LIF) were also significantly overexpressed
as well as monocyte chemotactic protein 1 (MCP-1)
and plasminogen activator inhibitor-1 (PAI-1). Adipose
tissue hormones were also identified. Resistin and lep-
tin relative expression levels were higher in aCM.
Interestingly though, a significant reduction in adipo-
nectin levels was observed in aCM.
Adipocyte-conditioned medium (aCM) increases
viability of PC3
The prostate cells PC3 were treated with aCM. The
result was an increased metabolic activity when MTT
assay was performed. Also, two dose response curves
were determined to 5a-dihydrotestosterone (DHT) and
to 17b-Estradiol (E2). The half maximal effective con-
centration (EC50) for such hormones on PC3 cell lines
were of 1 nM for DHT and 0.1 nM for 17b-Estradiol.
When compared to control group (PC3 with com-
plete medium), all experimental groups were signifi-
cantly different (p< .0001). Cancer cells submitted in
vitro to an environment enriched with adipocyte-
related secretome (aCM) demonstrate a metabolic
activity of 3,21 ± 0,10 times fold when compared to
control group. Also, cells growing with DHT 1.0 nM
and E2 0.1 nM increased their metabolic activity to
2.98 ± 0.11 times and 2.04 ± 0.22 times, respectively.
Likewise, metabolic activity also increased when
compared to control group when aCM was doped
with DHT 1.0 nM and E2 0.1 nM to 3.48 ± 0.07 times
and 2.98 ± 0.37, respectively (Figure 2(A)).
The injury assay or wound healing assay is an in
vitro test that is based in the fact that in culture, cells
will invade cell-free territories. Experimentally, the ter-
ritories are created artificially by removing a group of
cells of a confluent culture thus creating an injury or
wound. The more rapid the wound is closed, the most
aggressive are the cells due their invasion capacity.
Prostate cancer cells PC3 in culture 24 h after injury
were able to close 11.34 ± 4.41%. However, cell under
the effect of the aCM that contains all the growth fac-
tors, signaling molecules, cytokines derived from adi-
pose tissue were able to close the wound up to
62.08 ± 2.43%. Likewise, PC3 within the same condi-
tions of control arm but supplemented with DHT
1.0 nM were able to repair the injury up to
79.12 ± 3.76%. Finally, the wound closed 23.75 ± 8.76%.
When compared to control, the experimental groups
aCM and DHT were significantly different and have
increased the rate of wound repair of 5.5 ± 0.55 and
7.0 ± 0.85 times. Also, E2 treated cells also increase
2.0 ± 1.9 fold their injury repair but in a non-significant
manner (Figure 2(B)).
Discussion
Among the several known risk factors for PCa, age is
one of most important factor. Not only the incidence
increases but also aggressiveness is higher. Also, age
at the diagnosis is related to worst prognosis. In our
Portuguese male population attending to urology con-
sultation the age has strong relation (Figure 1,
Table 2) not only with its onset and incidence but also
with tumor aggressiveness which agrees with most
other studies [41–43]. Thus age has major impact on
prognosis, response to the treatments and survival
rate [44,45].
Obesity has long been suggested to be implicated
in the carcinogenesis of PCa through several molecular
Table 3. Pearson Correlations between clinical and biochemical profiles.
Variables
(statistics)
Endocrine Profile Metabolic Profile
LH TT E2 PROL LEPT HbA1c TAG CHOT HDL LDL VLDL
PSA q 0.019 20.212* 0.031 0.008 0.177 0.188 0.038 0.045 0.073 0.120 0.036
p-value .850 .032 .753 .934 .074 .057 .704 .648 .463 .226 .720
BMI q 0.183* 20.323** 0.034 0.215** 0.308** 0.152* 0.186* 0.128 0.042 0.058 0.133
p-value .014 .000 .650 .001 .000 .042 .012 .086 .577 .440 .075
Age q 0.277** 0.018 0.055 0.051 0.011 0.047 20.154* 20.248** 0.078 20.220** 0.138
p-value .000 .816 .463 .504 .889 .534 .041 .001 .301 .003 .068
BMI: Body Mass Index; tPSA– total Prostate Specific Antigen; LH: Luteinizing hormone; TT: Total Testosterone; E2: Estradiol; Prol: Prolactin; Lept: Leptin;
Hb A1c: Glycated hemoglobin A, fraction 1c; TAG: Triacylglycerols; CHOT: Cholesterol, total fraction; HDL: High-density lipoprotein; LDL: Low-density lipo-
protein; VLDL: Very low-density lipoprotein. p<.05; p<.001.
pathways that include sexual hormone axis, adipokines
biological signaling among other. Regarding obesity
and its contribution to PCa in our population, our
results show clear evidence that overweight and obes-
ity play a major role on PCa pathogenesis (Figure 1,
Table 2). In our population from the North of Portugal,
normal weight patients only 22.4% have PCa and the
other patients (77.6%) have some kind of benign pros-
tate pathology such as prostatitis or benign hyperpla-
sia. Interestingly, our sample shows higher scores of
Gleason scale increased in overweight patients and
again in obese patients with a strong significance
(p< .0001, v2). The contribution of BMI in our popula-
tion is in agreement to the several studies on the sub-
ject [3,46–48].
Grosman et al. [49] have discussed the complexity
of sexual hormone axis and Prostate cancer. In the
particular case of testosterone this gains a new mean-
ing. As aforementioned Muller et al. [24] identified no
association of testosterone or DHT with PCa incidence
nor Gleason grade. However, other authors, such as
Pierorazio et al. [19] no share the same opinion. Kim
et al. [50] in a very recent and critical work on the
debate of testosterone levels and PCa using big data
have found a significant contribution of total
Testosterone (TT) on PCa aggressiveness (Gleason
Score). This team has described that low levels of TT
have direct relationship with Gleason score. However,
the implication of TT is not confined to tumor aggres-
siveness. Levels of TT also correlate independently
with PSA and BMI. In a very interesting recent work,
Yassin et al. [51] have found that men receiving tes-
tosterone replacement therapy (TRT) reduced the inci-
dence of high risk prostate biopsies [51]. Peskoe et al.
[52] have made a nationwide study on this matter and
have found a positive correlation between circulating
levels of PSA with TT. Otherwise, Aref et al. [53] have
evidence circulating levels of PSA correlated inversely
with BMI. Our set of results confirm the findings of the
authors who share the opinion that low levels of TT
correlates with PCa aggressiveness [19,50] (Figure 1,
Table 2) and also the findings of Aref et al. [53] since
we also found strong significance between low levels
of TT and the BMI. However, our results regarding PSA
levels and TT we have found an inverse relationship
(Table 2) which does not agree with Peskoe et al.
study [52]. Nevertheless Rastrelli et al. [54] found that
PSA may act as a predictor of testosterone deficiency.
In conclusion, low levels of TT correlate with PCa
aggressiveness. The low levels of TT may have several
causes. The molecular endocrine mechanisms underly-
ing this observation may rely on upstream or down-
stream hormones, in particular Luteinizing Hormone
(LH), at upstream, or estrogens such as 17b-Estradiol
(E2) at downstream.
Measuring serum LH is of help, since the level of
this hormone indicates where the failure is located: in
the testis if serum LH is high (primary), or at the level
of the hypothalamus or pituitary if serum LH is low or
normal (secondary). In our sample no relationship was
Figure 2. Metabolic activity (A) and Aggressiveness (B) of prostate cancer cells PC3. (A) Metabolic activity was measure with MTT
assay (spectrophotometry) by fold increase in relation to the control (PC3 without any treatment). All assays were significantly dif-
ferent by t-test to control group (p< .0001). Differences between other groups were indicated by () which means p< .05. (B)
Aggressiveness in vitro was determined by the injury assay. The area was calculated with image J with “Wound Healing Tool”
macro and differences were significantly (p< .0001) after 24h. aCM: adipocyte-conditioned medium; DHT: 5a-Dihydrotestosterone;
E2:17b-Estradiol.
found between the serum levels of TT and LH
(p¼ .723, PCC) although inversly related. However, in
our patients, LH increased with BMI. This observation
may be justified by androgen receptor insensivity and/
or hypogonadal function due to obesity [21,55–57].
Due to the fact that testosterone is aromatized to
E2 within adipocytes and prostate cells, various pre-
clinical studies support the assumption that estrogen
plays an important role in PC development and pro-
gression [58,59]. Our sample also evidence that a dir-
ect correlation with TT and E2 (p< .0001, PCC) and
that levels of E2 are associated with higher scores of
Gleason scale, thus indicating its role on PCa aggres-
siveness. Still, no association was found independelty
with Age, PSA or BMI.
The physiological role of prolactin in the prostate
gland is not clearly understood. It has been associated
as a autocrine/paracrine signaling mediator of prostate
gland that may act in cancer cells initiation [60,61].
Also, low levels prolactin have associated to metabolic
syndrome [62]. In our sample we have found no rela-
tion between the two groups of patients (with or
without PCa). However, when levels of prolactin were
stratified into categories low, normal, and high and
compared with Gleason score suggests that low levels
of prolactin are related with increase aggressiveness.
Also our results show that for this population, the lev-
els of prolactin independetly correlate with obesity
which is in aggreement with the finding of Corona
et al. [62].
The scientific evidence regarding relationship
between prostate health, androgens and obesity
comes mainly through studies from HRT
[4,11,56,57,63–65]. We have speculated, accordingly to
other several scientists that adipose tissue must be
seen as another endocrine organ rather than only a
mere energy storage organ [66,67]. Likewise, members
of our group have confirmed in vitro and in vivo in a
mouse model the influence of adipocyte secreted adi-
pokines on prostate cells [68]. Regarding in vitro
experimental assays on PCa cell culture it was possible
to confirm the role of sexual hormones and the role
of the metabolic environment on tumor cells.
Finally, in what concerns to metabolic profile, there
were no significant differences to report with some
few exceptions. Triacylglycerols (TAGs) and lipoprotein
profile no significant different were found when com-
paring means of the two groups (patients with and
without PCa) nor correlations were found between
PSA levels and lipids/lipoproteins. Nevertheless, LDL
and VLDL levels were correlated with the increase of
PCa aggressiveness. In 2010 Grosman et al. have also
found some associations between lipoproteins and
PCa. In their study, researchers found that PCa
patients presented lower CHOT and HDL than BPH
and Controls [69].
Regarding metabolic environment studies, on
human prostate cancer cell PC3 our results resemble
those verified by us previously on mice prostate can-
cer cell RM1. Comparing both findings, adipocyte
secretome-enriched conditioned medium (aCM)
increased both cancer cell metabolic activity measured
by MTT assay. In the same manner, after injury assay,
cancer cells under an environment enriched by adipo-
cyte secretome were able to repair the wound more
rapidly (Figure 2). The rate of in vitro wound healing is
a good cellular biomarker of the ability to invade terri-
tories. As mentioned before, in vitro studies have also
evaluated the individual effects of DHT and E2.
Metabolic activity of tumor cells also increased with
both DHT and E2, but this effect was more expressive
in DHT. Also, significant differences were found in the
cells submitted to aCMþDHT in comparison to those
with aCM or DHT alone (Figure 2(A)). In a different
manner significant differences were found between
cells treated with aCMþ E2 when compared with E2
alone but no significant differences were found
between the cells treated with aCMþ E2 and aCM
alone. Also comparing the patterns of DHT with E2, E2
is not able to reach a grade of response as achieve by
TT or aCM alone. These results are in accordance to
the observation of wound healing assay, in the sense
that, besides E2 be able to reduce the injury more
expressively than the control group, the difference is
not significant (p¼ .673). Nonetheless, the aCM and
DHT repair the injury significantly faster than control
group, but under the effect of DHT alone cell can
grow even faster than aCM that contains a broad
number of signaling molecules and growth factors
secreted by adipocytes. The components existing in
the aCM may be related to prostate carcinogenesis
and aggressiveness, since they are composed by a
high number of low-grade inflammatory cytokines,
growth factors and enzymes, that not only promote
cancer but also its invasiveness. Some of the compo-
nent are active chemo-attractive macrophage mole-
cules and matrix metalloproteases that opens a path
to cancer cell migration as well as angiogenesis
[39,68,70,71]. Supporting this theory, we can refer
some of adipokines presented in our cellular model.
For example, ESM1 (Endothelial Cell-Specific Molecule
1 or endocan) that is found in aCM was refered as cor-
relates with not only with Gleason score but also with
the expression of androgen receptor in PCa [72].
Also, our aCM previous proteomic chaterization demon-
strated high levels of VEGF, TIMP, MCP-1, PAI-1, IL6
among others that have been extensively associated to
PCa pathogenesis not only in humans but also in vitro
[70,73–75]. This cellular model and microarrays may
also be used to address the question whether sex hor-
mones such testosterone are responsible for the pheno-
typic changes of inflammatory cytokines and acute
phase markers as it found in PCa patients [69,73,76].
Conclusions
We have demonstrated in the present work that in the
North of Portugal, patients with PCa are mainly over-
weight and obese. In 2015, in this region 2351 patients
were diagnosed. One major limitation of this study is
the fact that all participants have prostate disease since
were recruited in the Urology Department of a major
university central hospital from the region. Although all
the participants have prostate disease, the differences
between the two arms in study gain a more meaning-
ful significance. Thus, differences observed are linked to
cancer specifically and not only to a baseline disease of
the prostate gland. Also, the several clinical, biochem-
ical, and metabolic alterations that connect prostate
cancer and obesity together may be explain mainly by
the alteration of sexual endocrine axis involving testos-
terone upstream and downstream hormones. In brief,
obesity related-hormones and cytokines are responsible
for the volume expansion (hyperotrophy) and hyperpla-
sia of both adipocyte and tumor cells. The increase in
number of adipose cells increases the activity of aroma-
tase, thus converting testosterone to estrogens (mainly
estradiol). Also, adipocytes secrete low-grade inflamma-
tory molecules that, together with increased estradiol
are responsible for the decrease of LH reducing even
more testosterone levels that also contribute for the
pathogenesis of PCa. Besides we have not found signifi-
cant differences between Leptin and PCa aggressive-
ness or TT levels we have found significant relation
between this hormone and the increase of BMI.
Testosterone production by testis are also negatively
regulated by Leptin [77,78] thus we may not really
exclude their participation in the reduction of testoster-
one production on testis, based on literature (Figure 3).
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